Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;10(2):209-220.
doi: 10.21037/acs-2020-cfmcs-fs-197.

Continuous-flow left ventricular assist device versus orthotopic heart transplantation in adults with heart failure: a systematic review and meta-analysis

Bufan Zhang  1 , Shaohua Guo  2 , Jie Ning  3 , Yiai Li  4 , Zhigang Liu  1   4
Affiliations

Continuous-flow left ventricular assist device versus orthotopic heart transplantation in adults with heart failure: a systematic review and meta-analysis

Bufan Zhang et al. Ann Cardiothorac Surg. 2021 Mar.

Abstract

Background: Due to the lack of donor hearts, many studies have assessed the prognosis of heart failure (HF) patients treated with a continuous-flow left ventricular assist device (CF-LVAD). However, previous results have not been consistent and minimal data is available regarding long-term outcomes. There is no consensus on whether CF-LVAD as a bridge or destination therapy (DT) can equal orthotopic heart transplantation (HTx). The purpose of our study is to compare clinical outcomes between CF-LVAD and HTx in adults.

Methods: We searched controlled trials from PubMed, Cochrane Library, and Embase databases until July 1, 2020. The mortality at different time points and adverse events were analyzed among 12 included studies.

Results: No significant differences were found in mortality at one-year [odds ratio (OR) =1.08; 95% CI: 0.97-1.21], two-year (OR =1.01; 95% CI: 0.91-1.12), three-year (OR =1.02; 95% CI: 0.69-1.51), and five-year (OR =1.02; 95% CI: 0.93-1.11), as well as the comparison of stroke, bleeding, and infection between CF-LVAD as a bridge versus HTx. The pooled analysis of one-year mortality (OR =2.76; 95% CI: 0.38-20.18) and two-year mortality (OR =1.64; 95% CI: 0.22-12.23) revealed no significant difference between CF-LVAD DT and HTx. Comparisons of adverse events showed no differences in bleeding or infection, but a higher risk of stroke (OR =5.09; 95% CI: 1.74-14.84) for patients treated with CF-LVAD DT than with HTx.

Conclusions: CF-LVAD as a bridge results in similar outcomes as HTx within five years. CF-LVAD as a DT is associated with similar one-year and two-year mortality, but carries a higher risk of stroke, as compared with HTx.

Keywords: Heart failure (HF); bridge to transplantation (BTT); continuous-flow left ventricular assist device (CF-LVAD); destination therapy (DT); heart transplantation (HTx).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flow chart of the study selection process.
Figure 2
Figure 2
Forest plots for the mortality between CF-LVAD BTT vs. HTx. (A) One-year mortality, (B) two-year mortality, (C) three-year mortality, and (D) five-year mortality. CF-LVAD, continuous-flow left ventricular assist device; BTT, bridge to transplantation; HTx, heart transplantation; OR, odds ratio; CI, confidence interval.
Figure 3
Figure 3
Forest plots for the adverse events between CF-LVAD BTT vs. HTx. (A) Stroke, (B) bleeding, and (C) infection. CF-LVAD, continuous-flow left ventricular assist device; BTT, bridge to transplantation; HTx, heart transplantation; OR, odds ratio; CI, confidence interval.
Figure 4
Figure 4
Forest plots for the mortality between CF-LVAD DT vs. HTx. (A) One-year mortality and (B) two-year mortality. CF-LVAD, continuous-flow left ventricular assist device; DT, destination therapy; HTx, heart transplantation; OR, odds ratio; CI, confidence interval.
Figure 5
Figure 5
Forest plots for the adverse events between CF-LVAD DT vs. HTx. (A) Stroke, (B) bleeding, and (C) infection. CF-LVAD, continuous-flow left ventricular assist device; DT, destination therapy; HTx, heart transplantation; OR, odds ratio; CI, confidence interval.
See this image and copyright information in PMC

References

    1. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol 2016;13:368-78. 10.1038/nrcardio.2016.25 - DOI - PMC - PubMed
    1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-200. 10.1093/eurheartj/ehw128 - DOI - PubMed
    1. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001;345:1435-43. 10.1056/NEJMoa012175 - DOI - PubMed
    1. Cavarretta E, Marullo AGM, Sciarretta S, et al. A network meta-analysis of randomized trials and observational studies on left ventricular assist devices in adult patients with end-stage heart failure. Eur J Cardiothorac Surg 2019;55:461-7. 10.1093/ejcts/ezy285 - DOI - PubMed
    1. Kalya AV, Tector AJ, Crouch JD, et al. Comparison of Novacor and HeartMate vented electric left ventricular assist devices in a single institution. J Heart Lung Transplant 2005;24:1973-5. 10.1016/j.healun.2005.03.002 - DOI - PubMed